Spots Global Cancer Trial Database for pancreatic neuroendocrine tumors
Every month we try and update this database with for pancreatic neuroendocrine tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | NCT02842749 | Pancreatic Neur... | everolimus | 18 Years - | Novartis | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy | NCT01384617 | Pancreatic Canc... Pancreatic Cyst... Chronic Pancrea... Pancreatic Neur... Pancreatic Pseu... | Stapling closur... Roux-en-Y anast... | 20 Years - | Wakayama Medical University | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) | NCT03053999 | Multiple Endocr... Pancreatic Neur... Hyperparathyroi... | Genome Sequenci... Data Review | - | M.D. Anderson Cancer Center | |
| Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms | NCT02125929 | Pancreatic Neur... | Robotic surgery Laparoscopic su... Open surgery | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors | NCT01381822 | Advanced Renal ... Gastrointestina... Pancreatic Neur... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | NCT01121562 | Pancreatic Neur... | Sunitinib | 20 Years - | Pfizer | |
| Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors | NCT02586844 | Neuroendocrine ... Pancreatic Neur... | 18 Years - | University Health Network, Toronto | ||
| Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors | NCT02586844 | Neuroendocrine ... Pancreatic Neur... | 18 Years - | University Health Network, Toronto | ||
| Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | NCT02842749 | Pancreatic Neur... | everolimus | 18 Years - | Novartis | |
| Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms | NCT02125929 | Pancreatic Neur... | Robotic surgery Laparoscopic su... Open surgery | 18 Years - 80 Years | Peking Union Medical College Hospital | |
| Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria | NCT02841865 | Pancreatic Neur... | - | Grupo Espanol de Tumores Neuroendocrinos | ||
| The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors | NCT02282059 | Pancreatic Neur... | sunitinib | 18 Years - | Pfizer | |
| Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy | NCT01384617 | Pancreatic Canc... Pancreatic Cyst... Chronic Pancrea... Pancreatic Neur... Pancreatic Pseu... | Stapling closur... Roux-en-Y anast... | 20 Years - | Wakayama Medical University | |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | NCT02943733 | Neuroendocrine ... Neoplasms Cancer Tumors | TAS-102 Temozolomide Filgrastim Pegfilgrastim | 18 Years - | University of Wisconsin, Madison | |
| Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | NCT01121562 | Pancreatic Neur... | Sunitinib | 20 Years - | Pfizer | |
| Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | NCT01648465 | Gastrointestina... Pancreatic Tumo... Gastrointestina... Pancreatic Neur... | Everolimus | 18 Years - | Hellenic Cooperative Oncology Group | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | NCT02685553 | Pancreatic Neur... Clear Cell Rena... Solid Pseudopap... | NIR | 18 Years - 80 Years | Universita di Verona | |
| Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | NCT03623984 | Neuroendocrine ... Carcinoid | Gallium Dotatat... | 19 Years - 100 Years | University of Alabama at Birmingham | |
| Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | NCT02943733 | Neuroendocrine ... Neoplasms Cancer Tumors | TAS-102 Temozolomide Filgrastim Pegfilgrastim | 18 Years - | University of Wisconsin, Madison |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
